한글목차

구강붕해정 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 162억 달러에서 2026년에는 176억 2,000만 달러에 이르고, CAGR 8.8%로 성장할 전망입니다. 지금까지의 성장은 구강붕해정에 대한 낮은 인지도, 기존 정제의 우위, 소아 및 노인층에 대한 대응 부족, 병원 약국 채널에 대한 의존도, 전문의약품 제제 도입 지연 등이 원인으로 보입니다.

구강붕해정 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 244억 3,000만 달러에 이르고, CAGR은 8.5%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 구강붕해정제의 제형 기술 발전, 편의성과 복약 순응도에 대한 환자 선호도 증가, 온라인 및 소매 약국 네트워크 확대, 중추신경계(CNS) 및 소화기 질환의 유병률 증가, 항정신병제 및 항간질약 연구개발(R;D) 확대 등을 꼽았습니다. ;&D)의 확대 등을 들 수 있습니다. 예측 기간 동안 주요 동향으로는 삼키기 쉽고 환자 친화적인 제형에 대한 수요 증가, 소아 및 노인 환자층 확대, 병원 및 소매 약국 유통 채널의 성장, 속효성 치료제에 대한 관심 증가, 특수 의약품 부문에서 구강붕해정 채택 확대 등이 있습니다.

신경질환의 발생률 증가는 향후 몇 년 동안 구강붕해정 시장의 성장을 견인할 것으로 예측됩니다. 신경질환이란 뇌와 말초신경을 포함한 신경계에 영향을 미쳐 정상적인 신경기능을 저해하는 상태를 말합니다. 이러한 질환 증가 추세는 주로 평균 수명의 연장에 기인합니다. 알츠하이머병, 파킨슨병과 같은 노화 관련 질환이 더 흔해지면서 전체 환자 수가 증가하고 있습니다. 구강붕해정은 특히 연하장애(삼킴곤란) 및 인지기능 장애가 있는 환자들에게 보다 쉽고 빠르게 약을 복용할 수 있도록 함으로써 신경계 질환의 치료를 돕습니다. 이를 통해 치료 순응도를 높이고, 적절한 시기에 투약할 수 있어 치료 효과를 높일 수 있습니다. 예를 들어, 2023년 3월 미국 비영리단체 알츠하이머 협회가 발표한 바에 따르면, 65세 이상 미국인 중 약 670만 명이 알츠하이머형 치매를 앓고 있으며, 2060년까지 1,380만 명으로 증가할 것으로 예측했습니다. 따라서 신경질환 증가 추세가 구강붕해정 시장을 주도하고 있습니다.

경구붕해정 시장의 주요 기업들은 복약순응도를 높이고 치료 결과를 개선하기 위해 환자 중심의 약물 전달 시스템 등 혁신적인 제제 개발에 주력하고 있습니다. 환자 중심의 약물 전달 시스템은 약물 복용을 보다 쉽고 편안하게 하여 전체 치료 경험을 향상시킬 수 있도록 설계되었습니다. 예를 들어, 2025년 5월 미국 헬스케어 기업 비아트리스(Viatris Inc.)는 치료 저항성 정신분열증 치료제로 'Gen-Clozapine' 경구붕해정(ODT)을 캐나다에서 출시했습니다. 국내 최초의 클로자핀 ODT로 물 없이 입안에서 빠르게 분해되어 삼킴 곤란 및 복약 순응도에 어려움을 겪는 환자들에게 도움을 줄 수 있습니다. 본 제품은 다양한 용량(12.5mg, 25mg, 50mg, 100mg, 200mg)으로 제공되며, 확립된 치료 프로토콜에 따라 정밀한 용량 조절이 가능합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

An orally disintegrating tablet (ODT) is a type of tablet designed to rapidly dissolve or break down in the mouth without the need for water. It is especially beneficial for patients who have difficulty swallowing, providing a convenient and easy-to-administer alternative to conventional tablets.

The main drug classes of orally disintegrating tablets include antipsychotics, antiepileptics, central nervous system stimulants, anxiolytics, anti-Parkinsonian drugs, antihypertensives, nonsteroidal anti-inflammatory drugs, antiallergy drugs, proton pump inhibitors, and others. Antipsychotics, for example, are used to treat mental health conditions by reducing symptoms such as hallucinations and delusions. These tablets are indicated for multiple conditions, including central nervous system disorders, gastrointestinal diseases, cardiovascular disorders, allergies, and more. They are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and drugstores, and are used by various patient groups, including pediatric, adult, and geriatric populations.

Tariffs have affected the orally disintegrating tablet market by increasing the cost of imported active pharmaceutical ingredients (APIs) and excipients used in ODT production. Segments such as anti-psychotics, anti-epileptics, and central nervous system stimulants are particularly impacted, with regions including Asia-Pacific and Europe facing higher import duties. While tariffs have led to increased production costs and potential price adjustments, they also encourage domestic sourcing, local manufacturing expansion, and innovation in cost-effective formulations.

The orally disintegrating tablet market research report is one of a series of new reports from The Business Research Company that provides orally disintegrating tablet market statistics, including orally disintegrating tablet industry global market size, regional shares, competitors with a orally disintegrating tablet market share, detailed orally disintegrating tablet market segments, market trends and opportunities, and any further data you may need to thrive in the orally disintegrating tablet industry. This orally disintegrating tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orally disintegrating tablet market size has grown strongly in recent years. It will grow from $16.2 billion in 2025 to $17.62 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited awareness of orally disintegrating tablets, conventional tablet dominance, low pediatric and geriatric targeting, reliance on hospital pharmacy channels, slow adoption of specialty drug formulations.

The orally disintegrating tablet market size is expected to see strong growth in the next few years. It will grow to $24.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to technological advancements in odt formulation, increasing patient preference for convenience and compliance, growth of online and retail pharmacy networks, rising prevalence of cns and gastrointestinal disorders, expanding r&d in anti-psychotics and anti-epileptics. Major trends in the forecast period include rising demand for easy-to-swallow and patient-friendly dosage forms, expansion of pediatric and geriatric patient targeting, growth in hospital and retail pharmacy distribution channels, increased focus on rapid-onset therapeutics, rising adoption of specialty drug classes in odt formulations.

The rising incidence of neurological disorders is expected to drive growth in the orally disintegrating tablet market in the coming years. Neurological disorders are conditions that affect the nervous system, including the brain and peripheral nerves, disrupting normal neural functions. The increasing prevalence of these disorders is primarily due to longer life expectancy, as age-related conditions like Alzheimer's and Parkinson's disease become more common, resulting in a higher overall case load. Orally disintegrating tablets support neurological disorders by enabling easier and faster medication administration, especially for patients with swallowing difficulties (dysphagia) or cognitive impairments. This improves treatment adherence, ensures timely dosing, and enhances therapeutic effectiveness. For example, in March 2023, the Alzheimer's Association, a U.S.-based nonprofit, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the growing incidence of neurological disorders is driving the orally disintegrating tablet market.

Key companies in the orally disintegrating tablet market are focusing on innovative drug formulations, such as patient-centric delivery systems, to enhance adherence and improve outcomes. A patient-centric drug delivery system is designed to make medication easier and more comfortable to take, enhancing the overall treatment experience. For instance, in May 2025, Viatris Inc., a U.S.-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada for treatment-resistant schizophrenia. As the first clozapine ODT available in the country, it disintegrates quickly in the mouth without water, supporting patients with swallowing or adherence challenges. The product is offered in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling precise dose titration aligned with established treatment protocols.

In December 2024, Novo Holdings A/S, a Denmark-based life sciences investment firm, acquired Catalent, Inc. for $16.5 billion. This acquisition strengthens Novo Holdings' presence in contract development and manufacturing by partnering with a global leader in drug delivery and fill-finish services. Catalent, Inc., a U.S.-based CDMO, specializes in advanced drug-delivery technologies, including orally disintegrating tablets, softgels, and biologics fill-finish solutions.

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the orally disintegrating tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orally disintegrating tablet market consists of sales of benadryl orally disintegrating tablets (diphenhydramine), zofran orally disintegrating tablets (ondansetron), cialis orally disintegrating tablets (tadalafil), and lamictal orally disintegrating tablets (lamotrigine). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orally Disintegrating Tablet Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses orally disintegrating tablet market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orally disintegrating tablet ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The orally disintegrating tablet market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Anti-Psychotics; Anti-Epileptics; Central Nervous System Stimulants; Anxiolytics; Anti-Parkinsonian Drugs; Anti-Hypertensives; Non-Steroidal Anti-Inflammatory Drugs; Anti-Allergy Drugs; Proton Pump Inhibitors; Other Drug Classes
• 2) By Disease Indication: Central Nervous System Disease; Gastrointestinal Disease; Cardiovascular System Disorders; Allergy; Other Disease Indications
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Drug Stores
• 4) By Consumer Type: Pediatric; Adult; Geriatric
• Subsegments:
• 1) By Anti-Psychotics: Atypical Anti-Psychotics; Typical Anti-Psychotics
• 2) By Anti-Epileptics: Sodium Channel Blockers; GABA Analogs; Other Anti-Epileptics
• 3) By Central Nervous System Stimulants: Amphetamine Derivatives; Methylphenidate; Other CNS Stimulants
• 4) By Anxiolytics: Benzodiazepines; Non-Benzodiazepine Anxiolytics
• 5) By Anti-Parkinsonian Drugs: Dopamine Agonists; MAO-B Inhibitors; Other Anti-Parkinsonian Drugs
• 6) By Anti-Hypertensives: Beta-Blockers; Calcium Channel Blockers; ACE Inhibitors; Other Anti-Hypertensives
• 7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Diclofenac; Other NSAIDs
• 8) By Anti-Allergy Drugs: Antihistamines; Corticosteroids
• 9) By Proton Pump Inhibitors: Omeprazole; Esomeprazole
• 10) By Other Drug Classes: Antiemetics; Antimigraine Drugs; Other Therapeutic Classes
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Bayer AG; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Limited; Aurobindo Pharma USA Inc.; Dr. Reddy's Laboratories Limited; Cadila Healthcare Limited; Torrent Pharmaceuticals Limited; Adare Pharma Solutions.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Orally Disintegrating Tablet Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Orally Disintegrating Tablet Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Orally Disintegrating Tablet Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Orally Disintegrating Tablet Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Industry 4.0 & Intelligent Manufacturing
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Easy-To-Swallow And Patient-Friendly Dosage Forms
  • 4.2.2 Expansion Of Pediatric And Geriatric Patient Targeting
  • 4.2.3 Growth In Hospital And Retail Pharmacy Distribution Channels
  • 4.2.4 Increased Focus On Rapid-Onset Therapeutics
  • 4.2.5 Rising Adoption Of Specialty Drug Classes In Odt Formulations

5. Orally Disintegrating Tablet Market Analysis Of End Use Industries

• 5.1 Pediatric Patients
• 5.2 Adult Patients
• 5.3 Geriatric Patients
• 5.4 Hospitals And Clinics
• 5.5 Pharmacies

6. Orally Disintegrating Tablet Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Orally Disintegrating Tablet Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Orally Disintegrating Tablet PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Orally Disintegrating Tablet Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Orally Disintegrating Tablet Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Orally Disintegrating Tablet Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Orally Disintegrating Tablet Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Orally Disintegrating Tablet Market Segmentation

• 9.1. Global Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
• 9.2. Global Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
• 9.3. Global Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
• 9.4. Global Orally Disintegrating Tablet Market, Segmentation By Consumer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric, Adult, Geriatric
• 9.5. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Psychotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Atypical Anti-Psychotics, Typical Anti-Psychotics
• 9.6. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
• 9.7. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Central Nervous System Stimulants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
• 9.8. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anxiolytics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Benzodiazepines, Non-Benzodiazepine Anxiolytics
• 9.9. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Parkinsonian Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
• 9.10. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Hypertensives, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
• 9.11. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ibuprofen, Diclofenac, Other NSAIDs
• 9.12. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Allergy Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antihistamines, Corticosteroids
• 9.13. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Omeprazole, Esomeprazole
• 9.14. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

10. Orally Disintegrating Tablet Market Regional And Country Analysis

• 10.1. Global Orally Disintegrating Tablet Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Orally Disintegrating Tablet Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Orally Disintegrating Tablet Market

• 11.1. Asia-Pacific Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Orally Disintegrating Tablet Market

• 12.1. China Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Orally Disintegrating Tablet Market

• 13.1. India Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Orally Disintegrating Tablet Market

• 14.1. Japan Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Orally Disintegrating Tablet Market

• 15.1. Australia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Orally Disintegrating Tablet Market

• 16.1. Indonesia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Orally Disintegrating Tablet Market

• 17.1. South Korea Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Orally Disintegrating Tablet Market

• 18.1. Taiwan Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Orally Disintegrating Tablet Market

• 19.1. South East Asia Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Orally Disintegrating Tablet Market

• 20.1. Western Europe Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Orally Disintegrating Tablet Market

• 21.1. UK Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Orally Disintegrating Tablet Market

• 22.1. Germany Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Orally Disintegrating Tablet Market

• 23.1. France Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Orally Disintegrating Tablet Market

• 24.1. Italy Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Orally Disintegrating Tablet Market

• 25.1. Spain Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Orally Disintegrating Tablet Market

• 26.1. Eastern Europe Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Orally Disintegrating Tablet Market

• 27.1. Russia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Orally Disintegrating Tablet Market

• 28.1. North America Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Orally Disintegrating Tablet Market

• 29.1. USA Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Orally Disintegrating Tablet Market

• 30.1. Canada Orally Disintegrating Tablet Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Orally Disintegrating Tablet Market

• 31.1. South America Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Orally Disintegrating Tablet Market

• 32.1. Brazil Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Orally Disintegrating Tablet Market

• 33.1. Middle East Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Orally Disintegrating Tablet Market

• 34.1. Africa Orally Disintegrating Tablet Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Orally Disintegrating Tablet Market, Segmentation By Drug Class, Segmentation By Disease Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Orally Disintegrating Tablet Market Regulatory and Investment Landscape

36. Orally Disintegrating Tablet Market Competitive Landscape And Company Profiles

• 36.1. Orally Disintegrating Tablet Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Orally Disintegrating Tablet Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Orally Disintegrating Tablet Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Orally Disintegrating Tablet Market Other Major And Innovative Companies

• Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solution

38. Global Orally Disintegrating Tablet Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Orally Disintegrating Tablet Market

40. Orally Disintegrating Tablet Market High Potential Countries, Segments and Strategies

• 40.1 Orally Disintegrating Tablet Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Orally Disintegrating Tablet Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Orally Disintegrating Tablet Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer